What is Claimed is:

1. A compound of formula I



(formula I),

wherein

R^1 is -C(O)-NH-alkyl or -C(O)-N(alkyl)$_2$, which alkyl groups are unsubstituted or substituted with at least one substituent selected from

-OH;

-NH(alkyl);

-N(alkyl)$_2$;

-NH-C(O)-alkyl;

-C(O)-NH-alkyl;

-C(O)-N(alkyl)$_2$;

-C(O)-NH$_2$;

-O-alkyl;

-heterocyclyl;

-NH-heterocyclyl;

-NH-S(O)$_2$-alkyl;

-S(O)$_2$-NH$_2$; and

-S(O)-alkyl,

wherein when said at least one substituent contains an alkyl group, the alkyl group is unsubstituted or substituted with -OH;

or a group

-CN;

-C(O)-NH_2;

-C(O)-NH-heterocyclyl;

-C(O)-NH-NH-C(O)-NH_2; or

-C(O)-NH-NH-C(O)-alkyl, which alkyl is unsubstituted or substituted with

-NH(alkyl); or

-$N(alkyl)_2$; and

R^2 is halogen;

heterocyclyl;

alkyl;

-NH-C(O)-alkyl;

-NH-$S(O)_2$-alkyl;

-$(CH_2)_m$-$S(O)_2$-NH_2;

-$(CH_2)_m$-$S(O)_2$-$N(alkyl)_2$;

-$(CH_2)_m$-$S(O)_2$-NH-(alkyl);

-O-alkyl; or

-$S(O)_n$-alkyl,

wherein when R^2 contains an alkyl group, the alkyl group is unsubstituted or substituted by

-OH;

-O-alkyl;

-NH-alkyl; or

-$N(alkyl)_2$;

m is 0, 1, 2, 3, 4, 5 or 6;
n is 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

2. The compound of formula I according to claim 1,
wherein
R^1 is -C(O)-NH-alkyl or -C(O)-N(alkyl)$_2$, which alkyl groups are unsubstituted or substituted with at least one substituent selected from
-OH;
-NH(alkyl);
-N(alkyl)$_2$;
-NH-C(O)-alkyl;
-C(O)-NH-alkyl;
-C(O)-N(alkyl)$_2$;
-C(O)-NH$_2$;
-O-alkyl;
-heterocyclyl;
-NH-heterocyclyl;
-S(O)$_2$-NH$_2$; or
-S(O)-alkyl,
wherein when said at least one substituent contains an alkyl group, the alkyl group is unsubstituted or substituted with -OH;

or a group
-CN;
-C(O)-NH2;
-C(O)-NH-heterocyclyl;
-C(O)-NH-NH-C(O)-NH2; or
-C(O)-NH-NH-C(O)-alkyl, which alkyl is unsubstituted or substituted with

-NH(alkyl); or
-$N(alkyl)_2$; and

R^2 is halogen;
heterocyclyl;
-$(CH_2)_m$-$S(O)_2$-NH_2;
-$(CH_2)_m$-$S(O)_2$-$N(alkyl)_2$; or
-$(CH_2)_m$-$S(O)_2$-NH-(alkyl);
-O-alkyl; or
-$S(O)_n$-alkyl, which alkyl groups are optionally substituted by
-OH;
-O-(C_1-C_4)alkyl;
-NH-alkyl; or
-$N(alkyl)_2$;

m is 0, 1, 2, 3, 4, 5 or 6;
n is 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

3. The compound according to claim 2,
wherein R^2 is halogen;
and pharmaceutically acceptable salts thereof.

4. The compound according to claim 2,
wherein
R^2 is morpholin-4-yl;
-S-alkyl; or a group
-O-alkyl, which alkyl group is substituted with
-$N(alkyl)_2$;

and pharmaceutically acceptable salts thereof.

5. The compound according to claim 4, said compound selected from:
6-(2-Bromo-phenyl)-2-(3-methylsulfanyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid ((S)-pyrrolidin-2-ylmethyl)-amide,
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid ((S)-pyrrolidin-2-ylmethyl)-amide,
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid ((R)-pyrrolidin-2-ylmethyl)-amide, and
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-[1,2,3]triazol-1-yl-ethyl)-amide.

6. The compound according to claim 2,
wherein

R^1 is -C(O)-NH-alkyl, which alkyl group is substituted with
-OH;
-NH(alkyl);
-N(alkyl)$_2$; or
-S(O)$_2$-NH$_2$;

or a group
-C(O)-NH-piperidin-3-yl;
-C(O)-NH-pyrrolidin-3-yl;
-C(O)-NH-CH$_2$-pyrrolidin-2-yl; or
-C(O)-NH-(CH$_2$)$_2$-imidazol-4-yl; and

R^2 is morpholin-4-yl;
-S-alkyl;
-O-alkyl, which alkyl group is substituted with
-N(alkyl)$_2$; or
-S(O)$_2$-NH-alkyl, which alkyl group is substituted with
-OH; or
-O-(C_1-C_4)alkyl;

and pharmaceutically acceptable salts thereof.

7. The compound according to claim 6, said compound selected from:
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid [2-(3H-imidazol-4-yl)-ethyl]-amide,
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (S)-piperidin-3-ylamide,
6-(2-Bromo-phenyl)-2-(3-methylsulfanyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (S)-piperidin-3-ylamide,
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide,
6-(2-Bromo-phenyl)-2-(3-methylsulfanyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide, and
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-hydroxy-ethyl)-amide.

8. The compound according to claim 2,
wherein
R^1 is -C(O)-NH-alkyl, which alkyl group is substituted with
-OH;
-NH(alkyl);
-N(alkyl)$_2$; or
-S(O)$_2$-NH$_2$; and

R^2 is morpholin-4-yl;

and pharmaceutically acceptable salts thereof.

9. The compound according to claim 2, wherein
R^1 is -C(O)-NH-alkyl, which alkyl group is substituted with
-OH;
-NH(alkyl);
-N(alkyl)$_2$; or
-S(O)$_2$-NH$_2$; and

R^2 is -S-alkyl;

and pharmaceutically acceptable salts thereof.

10. The compound according to claim 2,
wherein
R^1 is -C(O)-NH-alkyl, which alkyl group is substituted with
-OH;
-NH(alkyl);
-N(alkyl)$_2$; or
-S(O)$_2$-NH$_2$; and

R^2 is -O-alkyl, which alkyl group is substituted with
-N(alkyl)$_2$;

and pharmaceutically acceptable salts thereof.

11. The compound according to claim 2,
wherein
R^1 is -C(O)-NH-alkyl, which alkyl group is substituted with
-OH;
-NH(alkyl);
-N(alkyl)$_2$; or
-S(O)$_2$-NH$_2$; and

R^2 is -S(O)$_2$-NH-alkyl, which alkyl group is substituted with
-OH; or
-O-(C_1-C_4)alkyl;

and pharmaceutically acceptable salts thereof.

12. The compound according to claim 2,
wherein

R^1 is -C(O)-NH-piperidin-3-yl;
-C(O)-NH-pyrrolidin-3-yl;
-C(O)-NH-CH_2-pyrrolidin-2-yl; or
-C(O)-NH-$(CH_2)_2$-imidazol-4-yl; and

R^2 is morpholin-4-yl;

and pharmaceutically acceptable salts thereof.

13. The compound according to claim 2,
wherein

R^1 is -C(O)-NH-piperidin-3-yl;
-C(O)-NH-pyrrolidin-3-yl;
-C(O)-NH-CH_2-pyrrolidin-2-yl; or
-C(O)-NH-$(CH_2)_2$-imidazol-4-yl; and

R2 is -S-alkyl;

and pharmaceutically acceptable salts thereof.

14. The compound according to claim 2,
wherein

R^1 is -C(O)-NH-piperidin-3-yl;
-C(O)-NH-pyrrolidin-3-yl;
-C(O)-NH-CH_2-pyrrolidin-2-yl; or
-C(O)-NH-$(CH_2)_2$-imidazol-4-yl; and

R^2 is -O-alkyl, which alkyl group is substituted with
-N(alkyl)$_2$;

and pharmaceutically acceptable salts thereof.

15. The compound according to claim 2,
wherein
R^1 is -C(O)-NH-piperidin-3-yl;
-C(O)-NH-pyrrolidin-3-yl;
-C(O)-NH-CH_2-pyrrolidin-2-yl; or
-C(O)-NH-$(CH_2)_2$-imidazol-4-yl; and

R^2 is -$S(O)_2$-NH-alkyl, which alkyl group is substituted with
-OH; or
-O-$(C_1$-$C_4)$alkyl;

and pharmaceutically acceptable salts thereof.

16. The compound according to claim 2,
wherein
R^1 is -CN;
R^2 is morpholin-4-yl;
-S-alkyl;
-O-alkyl, which alkyl group is substituted with
-$N(alkyl)_2$; or
-$S(O)_2$-NH-alkyl, which alkyl group is substituted with
-OH; or
-O-$(C_1$-$C_4)$alkyl;

and pharmaceutically acceptable salts thereof.

17. The compound according to claim 2,
wherein
R^1 is -C(O)-NH-alkyl, which alkyl group is unsubstituted or substituted a substituent selected from
-OH;
-NH(alkyl);

-$N(alkyl)_2$;
-NH-C(O)-alkyl;
-C(O)-NH-alkyl;
-$C(O)-N(alkyl)_2$;
-$C(O)-NH_2$;
-O-alkyl;
-S(O)-alkyl, and
-$S(O)_2-NH_2$;

wherein when said substituent contains an alkyl group, the alkyl group is unsubstituted or substituted with -OH; and

and

R^2 is halogen;

and pharmaceutically acceptable salts thereof.

18. The compound according to claim 17, said compound selected from
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-dimethylamino-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methoxy-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (3-dimethylamino-propyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (3-dimethylamino-2,2-dimethyl-propyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-acetylamino-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methylamino-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid carbamoylmethyl-amide;

6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-dimethylamino-1-methyl-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid methylcarbamoylmethyl-amide; and
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-dimethylamino-propyl)-amide.

19. The compound according to claim 17, said compound selected from
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid dimethylcarbamoylmethyl-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (3-methylamino-propyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-hydroxy-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (3-hydroxy-propyl)-amide;
(S)-6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2,3-dihydroxy-propyl)-amide;
(R)-6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2,3-dihydroxy-propyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfinyl-ethyl)-amide; and
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid [2-(2-hydroxy-ethanesulfinyl)-ethyl]-amide.

20. The compound according to claim 2,
wherein
R^1 is -C(O)-N(CH_3)alkyl, which alkyl group is unsubstituted or substituted with

-NH(alkyl);
-N(alkyl)$_2$; and

R^2 is halogen;

and pharmaceutically acceptable salts thereof.

21. The compound according to claim 20, said compound being 6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-dimethylamino-ethyl)-methyl-amide.

22. The compound according to claim 2, wherein

R^1 is -C(O)-NH-alkyl, which alkyl group is substituted with
morpholin-4-yl;
pyrrolidinyl;
2-oxo-imidazolidinyl;
2-oxo-pyrrolidinyl;
1-methyl-pyrrolidinyl;
3H-imidazolyl;
1,5-dimethyl-pyrazolyl; or
-NH-pyridinyl;

R^2 is halogen;

and pharmaceutically acceptable salts thereof.

23. The compound according to claim 22, said compound selected from 6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid [2-(2-oxo-imidazolidin-1-yl)-ethyl]-amide;

(R)-6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (pyrrolidin-2-ylmethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid [3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (3-morpholin-4-yl-propyl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid [2-(pyridin-2-ylamino)-ethyl]-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid [2-(3H-imidazol-4-yl)-ethyl]-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (1,5-dimethyl-1H-pyrazol-3-ylmethyl)-amide; and
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid ((S)-pyrrolidin-2-ylmethyl)-amide.

24. The compound according to claim 2,
wherein

R^1 is -C(O)-NH-alkyl, which alkyl group is substituted with
-NH-alkyl;
-$N(alkyl)_2$; or
-C(O)-NH-piperidin-4-yl; and

R^2 is morpholin-4-yl;
-S-alkyl; or
-O-alkyl, which alkyl group is substituted with
-N(alkyl)2;

and pharmaceutically acceptable salts thereof.

25. The compound according to claim 24, said compound selected from
6-(2-Bromo-phenyl)-2-(3-methylsulfanyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-dimethylamino-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-dimethylamino-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methylamino-ethyl)-amide;
6-(2-Bromo-phenyl)-2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-dimethylamino-ethyl)-amide;
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid piperidin-4-ylamide; and
6-(2-Bromo-phenyl)-2-(3-methylsulfanyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methylamino-ethyl)-amide.

26. The compound according to claim 2,
wherein

R^1 is -C(O)-NH-heterocyclyl;
-C(O)-NH-NH-C(O)-NH_2; or
-C(O)-NH-NH-C(O)-alkyl, which alkyl is unsubstituted or substituted with
-NH(alkyl); or
-N(alkyl)$_2$;

R^2 is halogen;

and pharmaceutically acceptable salts thereof.

27. The compound according to claim 26, said compound selected from
(R)-6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid piperidin-3-ylamide;
(S)-6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid piperidin-3-ylamide;

6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid piperidin-4-ylamide;
1-[6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carbonyl]semicarbazide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid N'-(2-dimethylamino-acetyl)-hydrazide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (1-methyl-piperidin-4-yl)-amide;
(S)-6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid pyrrolidin-3-ylamide;
(R)-6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid pyrrolidin-3-ylamide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (1H-pyrazol-3-yl)-amide;
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methyl-2H-pyrazol-3-yl)-amide; and
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (4-carbamoyl-1H-pyrazol-3-yl)-amide.

28. The compound according to claim 2,
wherein
R^1 is -C(O)-NH_2; and
R^2 is morpholin-4-yl;
-$(CH_2)_m$-$S(O)_2$-NH-(alkyl);
-$(CH_2)_m$-$S(O)_2$-NH_2; or a group
-O-alkyl, -$S(O)_n$-alkyl,
wherein when R^2 contains an alkyl group, the alkyl group is unsubstituted or substituted by
-OH;
-NH-alkyl; or

-$N(alkyl)_2$;

m is 0, 1, 2, 3, 4, 5 or 6;
n is 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

29. The compound according to claim 28, said compound is selected from
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid amide;
6-(2-Bromo-phenyl)-2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid amide;
6-(2-Bromo-phenyl)-2-(3-methylsulfanyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid amide;
6-(2-Bromo-phenyl)-2-(4-sulfamoyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid amide;
6-(2-Bromo-phenyl)-2-(3-methylsulfamoylmethyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid amide;
6-(2-Bromo-phenyl)-2-[3-(2-hydroxy-ethanesulfonyl)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid amide; and
6-(2-Bromo-phenyl)-2-(3-methanesulfonyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid amide.

30. The compound according to claim 2,
wherein
R^1 is -CN; and
R^2 is morpholin-4-yl;
-$S(O)_n$-alkyl; or a group
-O-alkyl, which alkyl group is unsubstituted or substituted by
-OH;
-NH-alkyl; or
-$N(alkyl)_2$;

n is 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

31. The compound according to claim 30, said compound selected from
6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carbonitrile; compound with trifluoro-acetic acid;
6-(2-Bromo-phenyl)-2-(3-methanesulfonyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carbonitrile;
6-(2-Bromo-phenyl)-2-[4-(2-diethylamino-ethoxy)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carbonitrile;
6-(2-Bromo-phenyl)-2-[4-(2-hydroxy-ethoxy)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carbonitrile;
6-(2-Bromo-phenyl)-2-[4-(2-ethylamino-ethoxy)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carbonitrile;
6-(2-Bromo-phenyl)-2-(3-methanesulfinyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carbonitrile; and
6-(2-Bromo-phenyl)-2-[3-(2-hydroxy-ethanesulfonyl)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carbonitrile.

32. The compound according to claim 1,
wherein
R^1 is -C(O)-NH-$(CH_2)_2$–NH-$S(O)_2$-CH_3; and

R^2 is halogen;
heterocyclyl;
alkyl;
-N-C(O)-alkyl;
-N-$S(O)_2$-alkyl;
-$(CH_2)_m$-$S(O)_2$-NH_2;
-$(CH_2)_m$-$S(O)_2$-N(alkyl)$_2$;

$-(CH_2)_m-S(O)_2-NH-(alkyl)$;
-O-alkyl; or
$-S(O)_n$-alkyl,
wherein when R^2 contains an alkyl group, the alkyl group is unsubstituted or substituted by
-OH;
-O-alkyl;
-NH-alkyl; or
$-N(alkyl)_2$;

m is 0, 1, 2, 3, 4, 5 or 6;
n is 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

33. The compound according to claim 32, said compound selected from 6-(2-Bromo-phenyl)-2-(4-morpholin-4-yl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide, 6-(2-Bromo-phenyl)-2-(3-methanesulfonylamino-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide, 6-(2-Bromo-phenyl)-2-[4-(2-hydroxy-ethoxy)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide, 6-(2-Bromo-phenyl)-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide, 6-(2-Bromo-phenyl)-2-(3-methoxy-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide, 2-(3-Acetylamino-phenylamino)-6-(2-bromo-phenyl)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide, 6-(2-Bromo-phenyl)-2-(4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-6-ylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide,

6-(2-Bromo-phenyl)-2-[3-(2-hydroxy-ethylsulfanyl)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonylamino-ethyl)-amide, and 6-(2-Bromo-phenyl)-2-(3-hydroxymethyl-2,3-dihydro-benzo[1,4]dioxin-6-ylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-methanesulfonyl-amino-ethyl)-amide.

34. The compound according to claim 2, said compound selected from
6-(2-Bromo-phenyl)-2-(4-fluoro-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (piperidin-2-ylmethyl)-amide,
6-(2-Bromo-phenyl)-2-(4-methanesulfinyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-hydroxy-ethyl)-amide,
6-(2-Bromo-phenyl)-2-(3-methanesulfinyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-hydroxy-ethyl)-amide,
6-(2-Bromo-phenyl)-2-[3-(2-hydroxy-ethylsulfamoyl)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-hydroxy-ethyl)-amide,
6-(2-Bromo-phenyl)-2-[4-(2-hydroxy-ethylsulfamoyl)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-hydroxy-ethyl)-amide,
6-(2-Bromo-phenyl)-2-(4-methanesulfinyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide,
6-(2-Bromo-phenyl)-2-(3-methanesulfinyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide,
6-(2-Bromo-phenyl)-2-[4-(2-hydroxy-ethoxy)-phenylamino]-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide, and
6-(2-Bromo-phenyl)-2-(3-methanesulfonyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide.

35. The compound according to claim 1
wherein

R^1 is -C(O)-NH-alkyl, which alkyl group is substituted by
-OH;
$-S(O)_2-NH_2$;

pyrrolidin-2-yl; and

R^2 is -NH-C(O)-CH_3;
-NH-$S(O)_2$-CH_3;
-CH2-OH; or
R^2 is fused to the phenyl ring to form a 4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiinyl moiety;

and pharmaceutically acceptable salts thereof.

36. The compound according to claim 35, said compound selected from
6-(2-Bromo-phenyl)-2-(3-hydroxymethyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-hydroxy-ethyl)-amide,
6-(2-Bromo-phenyl)-2-(3-hydroxymethyl-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide,
6-(2-Bromo-phenyl)-2-(4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-6-ylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (2-sulfamoyl-ethyl)-amide,
6-(2-Bromo-phenyl)-2-(4,4-dioxo-3,4-dihydro-2H-4lambda*6*-benzo[1,4]oxathiin-6-ylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (pyrrolidin-2-ylmethyl)-amide HCl salt,
6-(2-Bromo-phenyl)-2-(3-methanesulfonylamino-phenylamino)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (pyrrolidin-2-ylmethyl)-amide HCl salt, and
2-(3-Acetylamino-phenylamino)-6-(2-bromo-phenyl)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (pyrrolidin-2-ylmethyl)-amide HCl salt.

37. A process for the manufacture of the compound according to claim 1, comprising:
(a) converting the sulfide group in the compounds of the general formula (II)



formula (II),

into the corresponding sulfoxide group, which sulfoxide group is

(b) substituted by the respective anilines of formula (II-A)



formula (II-A)

wherein R^2 has the meaning given in claim 1, to give the compound of the general formula (IV)

formula (IV),



(c) converting the -COOH group in formula (IV) into an amide derivative of formula (I).

38. The process according to claim 37, further comprising:

(d) converting the primary amide derivative obtained from (c) into its corresponding 7-carbonitril derivative of formula (I).

39. The process according to claim 38, further comprising:

(e) converting said compound of the general formula (I), obtained from (c) or (d), into a pharmaceutically acceptable salt.

40. A method for the treatment of a disease mediated by an inappropriate activation of src family tyrosine kinases, comprising administering, to a patient in need thereof, a therapeutically effective amount of a compound according to formula I



(formula I),

wherein

R^1 is -C(O)-NH-alkyl or -C(O)-N(alkyl)$_2$, which alkyl groups are unsubstituted or substituted with at least one substituent selected from

-OH;

-NH(alkyl);

-N(alkyl)$_2$;

-NH-C(O)-alkyl;

-C(O)-NH-alkyl;

-C(O)-N(alkyl)$_2$;

-C(O)-NH_2;
-O-alkyl;
-heterocyclyl;
-NH-heterocyclyl;
-NH-$S(O)_2$-alkyl;
-$S(O)_2$-NH_2; and
-S(O)-alkyl,
wherein when said at least one substituent contains an alkyl group, the alkyl group is unsubstituted or substituted with -OH;

or a group
-CN;
-C(O)-NH_2;
-C(O)-NH-heterocyclyl;
-C(O)-NH-NH-C(O)-NH_2; or
-C(O)-NH-NH-C(O)-alkyl, which alkyl is unsubstituted or substituted with
-NH(alkyl); or
-$N(alkyl)_2$; and

R^2 is halogen;
heterocyclyl;
alkyl;
-NH-C(O)-alkyl;
-NH-$S(O)_2$-alkyl;
-$(CH_2)_m$-$S(O)_2$-NH_2;
-$(CH_2)_m$-$S(O)_2$-$N(alkyl)_2$;
-$(CH_2)_m$-$S(O)_2$-NH-(alkyl);
-O-alkyl; or
-$S(O)_n$-alkyl,
wherein when R^2 contains an alkyl group, the alkyl group is unsubstituted or substituted by

-OH;
-O-alkyl;
-NH-alkyl; or
-N(alkyl)$_2$;

m is 0, 1, 2, 3, 4, 5 or 6;
n is 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

41. The method according to claim 40, wherein the disease is cancer.

42. A pharmaceutical composition comprising a compound of formula I



(formula I),

wherein

R^1 is -C(O)-NH-alkyl or -C(O)-N(alkyl)$_2$, which alkyl groups are unsubstituted or substituted with at least one substituent selected from
-OH;
-NH(alkyl);
-N(alkyl)$_2$;
-NH-C(O)-alkyl;

-C(O)-NH-alkyl;
-C(O)-N(alkyl)$_2$;
-C(O)-NH$_2$;
-O-alkyl;
-heterocyclyl;
-NH-heterocyclyl;
-NH-S(O)$_2$-alkyl;
-S(O)$_2$-NH$_2$; and
-S(O)-alkyl,

wherein when said at least one substituent contains an alkyl group, the alkyl group is unsubstituted or substituted with -OH;

or a group
-CN;
-C(O)-NH$_2$;
-C(O)-NH-heterocyclyl;
-C(O)-NH-NH-C(O)-NH$_2$; or
-C(O)-NH-NH-C(O)-alkyl, which alkyl is unsubstituted or substituted with
-NH(alkyl); or
-N(alkyl)$_2$; and

R^2 is halogen;
heterocyclyl;
alkyl;
-NH-C(O)-alkyl;
-NH-S(O)$_2$-alkyl;
-(CH$_2$)$_m$-S(O)$_2$-NH$_2$;
-(CH$_2$)$_m$-S(O)$_2$-N(alkyl)$_2$;
-(CH$_2$)$_m$-S(O)$_2$-NH-(alkyl);
-O-alkyl; or
-S(O)$_n$-alkyl,

wherein when R2 contains an alkyl group, the alkyl group is unsubstituted or substituted by

-OH;

-O-alkyl;

-NH-alkyl; or

-N(alkyl)$_2$;

m is 0, 1, 2, 3, 4, 5 or 6;

n is 0, 1 or 2;

and pharmaceutically acceptable salts thereof.